Financial Summary (All financials)
| In millions, except per share items | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 |
| Revenues | 1,267.2 | 1,345.2 | 1,368.4 | 1,392.6 | 1,402.2 | 1,118.9 | 967.0 | 1,069.3 |
| Revenue growth | -5.8% | -1.7% | -1.7% | -0.7% | 25.3% | 15.7% | -9.6% | 15.0% |
| Cost of goods sold | 1,066.4 | 1,130.1 | 1,161.6 | 1,168.5 | 1,093.4 | 881.3 | 915.0 | 450.3 |
| Gross profit | 200.8 | 215.1 | 206.8 | 224.1 | 308.8 | 237.6 | 52.0 | 619.0 |
| Gross margin | 15.8% | 16.0% | 15.1% | 16.1% | 22.0% | 21.2% | 5.4% | 57.9% |
| Sales and marketing | 349.7 | 388.8 | 435.0 | 464.4 | 428.8 | 371.5 | 285.3 | 303.4 |
| Research and development | 191.5 | 196.5 | 216.0 | 208.5 | 190.3 | 138.0 | 117.6 | 135.3 |
| General and administrative | 88.6 | 99.9 | 96.6 | 98.3 | 81.7 | 73.4 | 54.0 | 60.2 |
| EBITA | 109.4 | 102.8 | 51.1 | 28.4 | 164.0 | 89.6 | 90.0 | 120.1 |
| EBITA margin | 8.6% | 7.6% | 3.7% | 2.0% | 11.7% | 8.0% | 9.3% | 11.2% |
| Amortization of intangibles | 10.5 | 12.9 | 19.8 | | 21.7 | 1.4 | 5.8 | 7.1 |
| EBIT | 98.9 | 89.9 | 31.3 | 28.4 | 142.2 | 88.2 | 84.2 | 113.0 |
| EBIT margin | 7.8% | 6.7% | 2.3% | 2.0% | 10.1% | 7.9% | 8.7% | 10.6% |
| Pre-tax income | 85.9 | 43.0 | -22.2 | 2.5 | 131.2 | 78.8 | 67.6 | 97.5 |
| Income taxes | 15.9 | 1.0 | -3.7 | 39.5 | 6.2 | 12.2 | 17.7 | 21.9 |
| Tax rate | 18.6% | 2.2% | 16.5% | 1579.9% | 4.7% | 15.4% | 26.2% | 22.4% |
| Earnings from continuing ops | 70.0 | 42.1 | -18.5 | -37.0 | 124.9 | 66.7 | 49.9 | 75.7 |
| Earnings from discontinued ops | | | 0.5 | 45.3 | 9.9 | 1.8 | | |
| Net income | 70.0 | 42.1 | -18.1 | 8.3 | 134.8 | 68.4 | 49.9 | 75.7 |
| Net margin | 5.5% | 3.1% | -1.3% | 0.6% | 9.6% | 6.1% | 5.2% | 7.1% |
| |
| Diluted EPS | $0.51 | $0.30 | ($0.11) | ($0.21) | $0.69 | $0.38 | $0.29 | $0.87 |
| Shares outstanding (diluted) | 137.4 | 142.0 | 167.3 | 176.9 | 181.2 | 176.4 | 171.1 | 87.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|